Based on the above assumptions, we propose a novel potential intervention strategy: targeting GPX3 and MYC by modulating specific gut microbiota metabolites (such as Diosgenin and DIF-3), thus achieving multi-level regulation of the RA pathological process. Here, MYC is linked to rheumatoid arthritis.